Circulating galectin-1 concentrations in systemic sclerosis: potential contribution to digital vasculopathy

International Journal of Rheumatic Diseases

Volumn 19, Issue 6, 2016, Pages 622-627

  Yanaba, Koichi ^a   Asano, Yoshihide ^a   Akamata, Kaname ^a   Noda, Shinji ^a   Aozasa, Naohiko ^a   Taniguchi, Takashi ^a   Takahashi, Takehiro ^a   Toyama, Tetsuo ^a   Ichimura, Yohei ^a   Sumida, Hayakazu ^a   Kuwano, Yoshihiro ^a   Miyazaki, Miki ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

digital ulcer; ELISA; galectin 1; systemic sclerosis; vasculopathy

Indexed keywords

GALECTIN 1;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DIFFUSE PIGMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIMITED CUTANEOUS SYSTEMIC SCLEROSIS; MAJOR CLINICAL STUDY; MALE; PHALANX CONTRACTURE; PRIORITY JOURNAL; SCAR; SYSTEMIC SCLEROSIS; TELANGIECTASIA; ULCER;

EID: 85028271393     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12288     Document Type: Article

References (28)

1. Matucci-Cerinic M, Kahaleh B, Wigley FM (2013) Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 65, 1953–62.
2. Toscano MA, Bianco GA, Ilarregui JM et al. (2007) Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8, 825–34.
3. Rabinovich GA, Baum LG, Tinari N et al. (2002) Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 23, 313–20.
4. Stillman BN, Hsu DK, Pang M et al. (2006) Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 176, 778–89.
5. Thijssen VL, Poirier F, Baum LG, Griffioen AW (2007) Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood 110, 2819–27.
6. Perillo NL, Pace KE, Seilhamer JJ, Baum LG (1995) Apoptosis of T cells mediated by galectin-1. Nature 378, 736–9.
7. Blaser C, Kaufmann M, Muller C et al. (1998) β-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol 28, 2311–9.
8. Rabinovich GA, Daly G, Dreja H et al. (1999) Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 190, 385–98.
9. Liu SD, Lee S, La Cava A, Motran CC, Hahn BH, Miceli MC (2011) Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease. Lupus 20, 473–84.
10. Offner H, Celnik B, Bringman TS, Casentini-Borocz D, Nedwin GE, Vandenbark AA (1990) Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. J Neuroimmunol 28, 177–84.
11. Baum LG, Blackall DP, Arias-Magallano S et al. (2003) Amelioration of graft versus host disease by galectin-1. Clin Immunol 109, 295–307.
12. Perone MJ, Bertera S, Shufesky WJ et al. (2009) Suppression of autoimmune diabetes by soluble galectin-1. J Immunol 182, 2641–53.
13. Santucci L, Fiorucci S, Rubinstein N et al. (2003) Galectin-1 suppresses experimental colitis in mice. Gastroenterology 124, 1381–94.
14. Taniguchi T, Asano Y, Akamata K et al. (2012) Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J Rheumatol 39, 539–44.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23, 581–90.
16. LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15, 202–5.
17. Steen VD, Powell DL, Medsger TAJ (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31, 196–203.
18. Sato S, Ihn H, Kikuchi K, Takehara K (1994) Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 37, 391–4.
19. Clements PJ, Lachenbruch PA, Seibold JR et al. (1993) Skin thickness score in systemic sclerosis: an assessment of interobeservar variability in 3 independent studies. J Rheumatol 20, 1892–6.
20. Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28, 78–85.
21. Generini S, Matucci Cerinic M (1999) Raynaud's phenomenon and vascular disease in systemic sclerosis. Adv Exp Med Biol 455, 93–100.
22. Suematsu M, Wakabayashi Y, Ishimura Y (1996) Gaseous monoxides: a new class of microvascular regulator in the liver. Cardiovasc Res 32, 679–86.
23. Butler AR, Flitney FW, Williams DL (1995) NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci 16, 18–22.
24. Thijssen VL, Postel R, Brandwijk RJ et al. (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103, 15975–80.
25. Baum LG, Seilhamer JJ, Pang M, Levine WB, Beynon D, Berliner JA (1995) Synthesis of an endogeneous lectin, galectin-1, by human endothelial cells is up-regulated by endothelial cell activation. Glycoconj J 12, 63–8.
26. He J, Baum LG (2006) Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab Invest 86, 578–90.
27. Ito K, Scott SA, Cutler S et al. (2011) Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis 14, 293–307.
28. Seropian IM, Cerliani JP, Toldo S et al. (2013) Galectin-1 controls cardiac inflammation and ventricular remodeling during acute myocardial infarction. Am J Pathol 182, 29–40.